KILITCH DRUGS INDIA LTD Fair Value
KILITCH · Healthcare · Current price ₹182.19
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹80 | 13% ROE fading to 13% over ~3 yrs, on ₹80 book |
| Relative P/E | ₹262 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹125 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is KILITCH DRUGS INDIA LTD undervalued?
DocStoX estimates the fair value of KILITCH DRUGS INDIA LTD at ₹138 per share, versus the current market price of ₹182. That puts the stock about -24.1% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹80), Relative P/E (₹262), Graham floor (₹125). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹80 (bear) to ₹138 (base) to ₹262 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on KILITCH DRUGS INDIA LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.